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Introduction of national guidelines for
restrictive blood transfusion threshold for
hip fracture patients––a consecutive cohort
study based on complete follow-up in
national databases
Bjarke Viberg1,2,3,4* , Per Hviid Gundtoft1, Jesper Schønnemann5, Lasse Pedersen6, Lis Røhl Andersen1,
Kjell Titlestad7, Carsten Fladmose Madsen2, Jens Lauritsen2,3 and Søren Overgaard2,3
Abstract
Background: Randomized controlled trials have demonstrated that a restrictive red blood cell (RBC) transfusion strategy
lowers transfusion frequency without affecting mortality. However, the external validity of these trials has not been tested
in a large cohort. The purpose was to estimate the effect of introducing a National Clinical Guideline (NCG) for a
restrictive hemoglobin transfusion threshold on transfusion frequency and mortality in hip fracture patients > 65 years old.
Methods: A consecutive cohort study of hip fracture patients > 65 years old residing in the southern region of Denmark
was conducted using prospectively gathered data from registers during two separate 1-year time periods. The first period
from October 1, 2012, to September 30, 2013, included 1494 patients and used a liberal transfusion threshold, whereas
the second period from October 1, 2015, to September 30, 2016, including 1414 participants used a restrictive threshold
from the NCG. Participant data for age, sex, body mass index, Charlson Comorbidity Index, time to surgery, and death
were retrieved from the Danish Interdisciplinary Registry of Hip Fractures and were merged with RBC transfusion and
medication data extracted from the Danish Transfusion and Odense Pharmacoepidemiological Databases, respectively.
Cox proportional hazards models were used to test relative mortality risk for the restrictive group compared with the
liberal group at 30 and 90 days.
Results: Overall RBC transfusions decreased from 42 to 30% (p < 0.001). The 30-day mortality rate (95% CI) was 9% (8;11)
in the restrictive group and 13% (11;14) in the liberal group (p < 0.008), whereas the adjusted relative mortality risk was 0.
72 (0.57;0.91). The 90-day mortality rate was 15% (13;17) in the restrictive group and 19% (17;21) in the liberal group,
whereas the adjusted relative mortality risk was 0.78 (0.65;0.94).
Conclusion: These data suggest that the introduction of an NCG on restrictive blood transfusion leads to lower
transfusion frequency in hip fracture patients > 65 years old. Even though this reduction is associated with decreased
mortality at both 30 and 90 days, it may be explained by other issues than restrictive transfusion strategy. There has been
an improvement in the mortality of hip fracture patients in Denmark, and we suggest that a restrictive transfusion
strategy does not lead to increased mortality.
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Background
Blood loss leading to anemia commonly occurs in hip
fracture patients, resulting in approximately half of them
receiving RBC transfusions [1, 2]. RBC transfusions are
associated with complications such as transfusion-
associated circulatory overload, acute hemolysis, and
acute lung injury. Importantly, these and other events
increase patient morbidity and mortality [3].
Accordingly, in attempts to avoid transfusion-associated
complications, a restrictive RBC transfusion strategy has
been introduced using a hemoglobin threshold of 8 g/dL as
opposed to the liberal 10 g/dL. It is claimed that this
approach does not affect mortality, functional recovery, or
postoperative morbidity in hip fracture patients [4]. Never-
theless, the previous Cochrane review [4] on this topic
demonstrated low-quality evidence specific to hip fracture
patients, whereas a more recent Cochrane review [5] refer-
encing a broader range of clinical specialties found that
compared with the liberal transfusion threshold, a restrict-
ive hemoglobin threshold of 7 to 8 g/dL decreased the RBC
proportion by 43% while also demonstrating evidence sup-
porting no significant impact on 30-day mortality or mor-
bidity. A recent systematic review [6] also suggests that
patients with cardiovascular disease undergoing non-
cardiac surgery should be set at a threshold of 8 g/dL since
a lower threshold may not be safe.
While the National Institute for Health and Care
Excellence (NICE) guidelines from 2015 [7] recommend
a restrictive transfusion threshold, it is important to note
that this is based on very low- to low-quality evidence.
Because the NICE guidelines are based exclusively on ran-
domized controlled trials (RCT), there is an additional
need for data based on pragmatic trials such as those
involving population studies without exclusion of individ-
uals. Therefore, this study aimed to estimate the effect of
introducing an NCG for a restrictive hemoglobin transfu-
sion threshold on transfusion frequency and mortality in
individuals > 65 years of age with a hip fracture.
Methods
Study design
This consecutive cohort study included patients demon-
strating a hip fracture within two separate 1-year time pe-
riods, prior to and following the introduction of the NCG.
The first time period was between October 1, 2012, and
September 30, 2013, which was the control period (here-
after referred to as the liberal group). The second time
period was between October 1, 2015, and September 30,
2016, which was the intervention period adhering to the
Danish NCG [8] for blood component transfusion indica-
tions (hereafter referred to as the restrictive group).
Reporting of data is performed according to the RECORD
extension to the STROBE guidelines [9].
Setting
The present study was performed in four independent
public hospitals in the Southern Region of Denmark,
encompassing the entire territory consisting of 1.22 mil-
lion inhabitants. The Danish National Health Service pro-
vides tax-supported free healthcare and general hospital
care for all Danish citizens [10]. Since it is not typical for
acute hip fracture patients to be treated in the few
remaining private hospital clinics, but when this does
occur, reporting is mandatory, patients included in this
study comprise a consecutive and complete series. Prior
to the introduction of the NCG in 2014, the blood transfu-
sion limit was 7.2 g/dL for healthy individuals, with a level
of 9.7 g/dL used for individual assessment (e.g., age, rate
of anemia, clinical condition, and type of anemia) [11].
The NCG from 2014 references 7.0 g/dL as the lowest
transfusion limit for any patient or those demonstrating
symptoms of anemia and 8.0 g/dL if the patient has
chronic heart disease [8]. This is illustrated in Table 1. In
addition, the NCG from 2014 also set a limit of 9.0 g/dL
for patients demonstrating an acute coronary syndrome.
Participants
The Danish Interdisciplinary Registry of Hip Fracture
database was used to identify the study population. This
included all patients admitted with a hip fracture (ICD-10
codes DS720, DS721, and DS722) to one of the four public
hospitals in the Southern Region of Denmark. Procedure
codes [12] were used to categorize the type of surgery.
Variables
Participant information for age, sex, body mass index
(BMI), Charlson Comorbidity Index (CCI) [13], time to
surgery, and death were retrieved from the Danish Inter-
disciplinary Registry of Hip Fractures. The CCI is calcu-
lated by using diagnoses reported to the Danish National
Patient Register up to 10 years prior to a hip fracture op-
eration. Patient data regarding hemoglobin was retrieved
from the department of Clinical Biochemistry and
Pharmacology at the Odense University Hospital, which
is able to retrieve data from the whole region. Data
regarding transfusion with red blood cells (RBC) was re-
trieved from the Danish Transfusion Database [14]. Data
on patient medication, if reimbursed within 100 days prior
to admission to hospital, was retrieved from the Odense
Pharmacoepidemiological Database [15].
Table 1 Transfusion thresholds for the liberal and restrictive
guidelines
Liberal Restrictive
Healthy patients 7.2 7.0
Patients with chronic heart disease 9.7* 8.0
*Individual assessment was applied using age, rate of anemia, clinical
condition, and type of anemia instead of chronic heart disease
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Data sources
The Danish Interdisciplinary Registry of Hip Fractures is a
population-based clinical quality database established in
2003 and includes data on all hip fracture patients aged 65
or older. Reporting of hip fractures is mandatory for all
hospital units, and a number of pre- and peri-operative data
are prospectively collected, which includes data on quality
of patient care [16]. The Danish Interdisciplinary Registry
of Hip Fractures database was linked to the Danish
National Patient Registry database in order to extract
patient information for BMI, CCI, and reoperations [17].
The Danish National Patient Registry database con-
tains data for all hospital admissions since 1977, which
includes dates of admission and discharge, diagnoses
(ICD 8 1977-1993, ICD 10 1994 onwards) at discharge
and surgical procedure dates and codes according to the
Nordic Medico-Statistical Committee (NOMESCO) clas-
sification [12]. The Danish Interdisciplinary Registry of
Hip Fractures database is also linked to the Danish Civil
Registration System database containing information on
changes in vital status (e.g., death, new civil registration
number, lost, no residence) and migration for the entire
Danish population dating back to 1968 [10].
The Danish Transfusion Database is also a population-
based clinical quality database maintained since 2006 and
linked to the Danish National Patient Registry database.
The Danish Transfusion Database contains data from blood
bank registries, patient administrative systems, and clinical-
biochemical registries. The Odense Pharmacoepidemiologi-
cal Database is a region-specific prescription database,
which covers all inhabitants in the Southern Region of
Denmark since 2007. The Odense Pharmacoepidemiologi-
cal Database contains data for any drug prescription written
by hospital staff or general practitioners. However, drug re-
cords do not include benzodiazepines, other hypnotics,
drugs used to promote weight loss or tobacco abstinence,
oral contraceptives, certain antibiotics (e.g., quinolones, tet-
racyclines), and those that are dispensed over the counter.
Bias
For this study, data has been included for medication as
well as comorbidities in attempts to minimize biases by
indication. However, we acknowledge that we are not
able to include information on clinical condition nor
rate and type of anemia, which are potentially relevant
data omissions in terms of RBC transfusion.
Study size
The survival sample size for finding a reduction of RBC
transfusion events yielded 1112 patients for each group.
Event for RBC transfusion was set to 50% [1], censoring
including death was set to 15%, and minimal clinical
difference was set to a hazard ratio of 1.2.
Quantitative variables
Age was categorized as 65–74, 75–84, and ≥ 85 years
old. Three comorbidity levels were defined: a score of 0
(low) was given to patients with no previous record of
diseases included in the CCI, a score of 1–2 (medium),
and a score of 3 or more (high). Pharmacotherapy use
was categorized using dichotomous values (yes/no) for
NSAIDs, antihypertensives, glucocorticoids, antidepres-
sants, statins, anticoagulants, and immunosuppressants.
Statistics
The study population was divided into two comparison
groups: group 1 was the restrictive transfusion group fol-
lowing implementation of the NCG (time period October
1, 2015–September 30, 2016), and group 2 was the control
group defined as the liberal transfusion group (time period
October 1, 2012–September 30, 2013). The statistician
was blinded to the groups’ time periods. We described the
study population according to the distribution of patients’
characteristics, tabulating the numbers and percentages of
patients. Fisher’s exact test was used to evaluate differences
between groups for variables of interest. Two-tailed signifi-
cance was determined using an alpha level set at 0.05.
Mortality at 30 and 90 days was assessed using Kaplan–
Meier analyses, with all patients followed until death, emigra-
tion, or end of the follow-up period. Relative mortality risk for
the intervention group compared with the control group at
30 and 90 days was estimated using Cox proportional hazards
modeling. The proportional hazard assumption was tested via
log-minus-log plots and was not violated. We adjusted
models for age (i.e., 65–74; 75–84, ≥ 85 years), sex, CCI (i.e.,
0, 1–2, ≥ 3), and type of surgery (e.g., cannulated screws, slid-
ing hip screw, intramedullary nail, and hip arthroplasty). All
outcomes were estimated with a 95% confidence interval (CI).
Data access, linkage, and cleaning methods
The authors had complete access to aggregated data from
the Danish Interdisciplinary Registry of Hip Fractures,
Danish Transfusion Database, and Odense Pharmacoepi-
demiological Database. The civil registration system con-
tains data for individual unique and unchangeable civil
registration numbers, which are assigned to all Danish cit-
izens at date of birth or immigration. The civil registration
number is recorded in all Danish registers, which allows
for unambiguous linkage between registers on an individ-
ual basis. Furthermore, the civil registration systems hold
information on date of birth, sex, emigration, and death.
The prevalence of disappearing persons is 0.3%, which al-
lows for almost complete follow-up for all patients [10].
Results
The dataset from the Danish Interdisciplinary Registry of
Hip Fractures yielded 1494 patients stratified to the liberal
group and 1414 for the restrictive group (Table 2). The two
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Table 2 Demographic data of the study population and divided by the two cohorts
Study population Liberal group Restrictive group
n % n % n % p<
Total 2908 100 1494 100 1414 100
Age
65–74 590 20 308 21 282 20
75–84 1018 35 514 34 504 36 0.766
≥ 85 1300 45 672 45 628 44
Sex
Female 2.014 69 1065 71 949 67 0.015
Male 894 31 429 29 465 33
CCI
None (0) 1019 35 526 35 493 35 0.800
Low (1–2) 1238 43 641 43 597 42
High (≥ 3) 651 22 327 22 324 23
BMI
< 18.5 278 10 153 10 125 9
18.5–24.9 1269 44 645 43 624 44
25–29.9 686 24 341 23 345 24 0.433
≥ 30 210 7 102 7 108 8
Missing 465 16 253 17 212 15
Prescription medicine
NSAID 223 8 137 9 86 6 0.002
Diabetes 330 11 166 11 164 11 0.66
Anticoagulant 1191 41 620 42 571 41 0.58
Antihypertensive 1457 50 757 51 700 49 0.58
Statin 720 25 356 24 364 26 0.22
Glucocorticoid 172 6 89 6 83 6 0.94
Depression medicine 888 31 486 33 402 29 0.02
COPD medicine 399 14 209 14 190 13 0.69
Type of fracture
Femoral neck 1693 59 875 59 818 58 0.851
Pertrochanteric 948 32 480 33 468 33
Subtrochanteric 267 9 139 9 128 9
Type of surgery
Cannulated screws 383 13 206 14 177 13 0.001
Sliding hip screw 677 23 404 27 273 19
Intramedullary nail 787 27 357 24 431 30
Arthroplasty 1018 35 506 34 512 36
Miscellaneous 42 1 21 1 21 1
Time to surgery
< 24 h 2050 72 1104 74 946 69
24–48 h 636 22 317 21 319 23 0.001
> 48 h 180 6 65 4 115 8
NSAID nonsteroidal anti-inflammatory drug, COPD chronic obstructive pulmonal disease
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groups did not differ for age (p < 0.766), whereas there
were more males in the restrictive group (p < 0.015). There
were no group differences for comorbidities (p < 0.80) or
type of fracture (p < 0.851), whereas more intramedullary
nails were used in the restrictive group (p < 0.001). The
surgical delay was also longer for the restrictive compared
with the control group (p < 0.001).
In the period following the introduction of the NCG,
overall RBC transfusion proportion was reduced from 42
to 30% (p < 0.001) (Table 3). One hospital decreased trans-
fusion rates from 43 to 19%, whereas another hospital did
not lower it at all. The mean hemoglobin level at admission
was 12.3 (12.2;12.3), with no group differences (p < 0.540)
(Table 4). At the time of first transfusion, the liberal group
demonstrated a mean (95% CI) hemoglobin level equal to
9.1 (9.0;9.2), which was compared with the restrictive
group at 8.5 (8.2;8.4) (p < 0.001). The transfusion threshold
differed between the two periods, as 19% of the RBC trans-
fusion was given at a hemoglobin level < 8.0 g/dL in the
liberal period compared with 47% in the restrictive period
(Table 5).
In a subgroup analysis for patients demonstrating a
hemoglobin level between 7.0 and 8.9 g/dL (n = 1101),
which constituted patients with a possible indication for
RBC transfusion, 80.7% received an RBC transfusion in the
liberal group compared with 58.6% for the restrictive group.
Overall, 30-day mortality was 11% (10;12); in the re-
strictive group, it was 9% (8;11), and in the liberal group,
it was 13% (11;14) (p < 0.008). The crude relative mortal-
ity risk at 30 days was 0.80 (0.56;1.12) for the restrictive
group compared with the liberal group. However, after
adjusting for age, sex, CCI, medication, time to surgery,
and type of surgery, the relative mortality risk was 0.72
(0.57;0.91). Overall, 90-day mortality was 17% (16;10); in
the restrictive group, it was 15% (13;17), and in the lib-
eral group, it was 19% (17;21). Comparing the restrictive
to the liberal group, the crude relative mortality risk was
0.91 (0.69;1.19), whereas the adjusted relative mortality
risk was 0.78 (0.65;0.94).
In the subgroup analysis for patients demonstrating a
hemoglobin level between 7.0 and 8.9 g/dL (n = 1101),
there was a 30-day mortality proportion equal to 13% (0.
10;0.16) in the restrictive period compared with 10% (0.
08;0.13) for the liberal period.
Discussion
Using a population-based study design of hip fracture
patients, the present study reported on transfusion fre-
quency and mortality following the introduction of the
NCG on restrictive blood transfusion. These data sug-
gest that the lower hemoglobin threshold for RBC trans-
fusion does not increase mortality for older patients
with a hip fracture. This observation is consistent with
the current literature suggesting there is no difference in
patient outcomes between restrictive and liberal treat-
ment strategies [4]. One RCT [18], however, has demon-
strated a higher mortality with the restrictive treatment
strategy, but this was only for nursing home patients
and only per protocol analysis, not the intention-to-treat
analysis. This particular RCT is therefore restricted to a
small subgroup of hip fracture patients. In contrast, we
found a decreased mortality in the restrictive period,
which was for all patients, including those with a
hemoglobin > 9.0 g/dL. In our data, we see a baseline
difference in time to surgery, which is longer in the re-
strictive group. This may be due to the introduction of
new oral anticoagulants (NOAC), which is usually
equivalent to a 2-day postponement of surgery to reduce
operative bleeding [19]. An increased time to surgery is
associated with an increased mortality risk [20], which
therefore could lead to an increased risk of mortality in
the restrictive group. However, an important bias for
mortality is the continuous work for improvement in
mortality, and the lowered mortality may therefore lie in
Table 3 Patients admitted and receiving red blood cell transfusion divided by hospital and group
Liberal group Restrictive group
Admitted Transfused n Transfused % (95% CI) Admitted Transfused n Transfused % (95% CI) p < for transfusion %
Total 1494 628 42 (40;45) 1414 430 30 (28;33) 0.001
Hospital 1 640 268 42 (38;46) 577 145 25 (21;29) 0.001
Hospital 2 312 135 43 (38;49) 283 99 35 (29;41) 0.039
Hospital 3 263 113 43 (37;49) 233 44 19 (14;24) 0.001
Hospital 4 279 112 40 (34;46) 321 142 44 (39;50) 0.311
Table 4 Mean hemoglobin level (g/dl) at admission and prior to first red blood cell transfusion by group
All patients Liberal group Restrictive group
Mean (95% CI) Mean (95% CI) Mean (95% CI) p<
Total, admission 12.3 (12.2;12.3) 12.3 (12.2;12.4) 12.3 (12.2;12.4) 0.54
Total, first transfusion 8.8 (8.7;8.9) 9.1 (9.0;9.2) 8.5 (8.2;8.4) 0.001
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other unmeasured aspects since the mortality for hip
fracture patients has improved over the last 35 years
[21]. An important factor in improving the mortality for
hip fracture patients is a multidisciplinary approach [22],
and especially an integrated orthogeriatric care [23]. We
therefore not interpret the demonstrated decreased mor-
tality as a direct cause to the introduction of a restrictive
transfusion strategy.
Being a cohort study, there may be uncontrolled bias.
There are several baseline differences which could
constitute significant biases. One is the slightly higher
proportion of females in the restrictive group, with two
retrospective cohort studies [24, 25] finding an odds
ratio of 1.5 for females receiving RBC transfusion com-
pared to males. In contrast, Johnston et al. [26] demon-
strated in a cohort study of 3625 patients that males had
a hazard ratio of 1.8 upon receiving an RBC transfusion
compared with females, whereas three other studies did
not observe any difference in risk associated with receiv-
ing RBC transfusions between males and females [27–29].
Therefore, we suggest that differences between the male
and female proportion in this study does not constitute
meaningful bias. A second baseline difference is a higher
proportion of intramedullary nails in the restrictive group.
A shift from sliding hip to intramedullary nails are also
seen in other Scandinavian countries [30, 31] resulting in
a lower reoperation for complex pertrochanteric fractures
[32]. A higher use of intramedullary nails in the restrictive
group may increase the likelihood of having a transfusion
[24, 25, 28, 33]. This would potentially lead to a slightly
higher transfusion proportion in the restrictive group. Ac-
cordingly, while the difference in transfusion proportion
between the groups could be due to different baselines, we
are certain that the reason for a lower RBC transfusion
proportion in the restrictive group is due to the lower
hemoglobin threshold.
Our large cohort study confirms that a restrictive RBC
transfusion threshold does not affect mortality and even
though the included studies are of low-quality, a meta-
analysis demonstrates no difference in functional recov-
ery or postoperative morbidity in hip fracture patients
when comparing restrictive and liberal transfusion
thresholds [4]. So why hold on to a liberal transfusion
threshold? RBC transfusions are not without compli-
cations and specific complications such as
transfusion-associated circulatory overload (TACO),
acute hemolysis, and transfusion-related acute lung
injury (TRALI) can all cause further morbidity and
mortality [3]. There may even be a higher association
with infections when treated with RBC transfusion
[34]. These considerations in combination with our
findings should lead to a restrictive transfusion
threshold for hip fracture patients.
This study has prospectively collected data from sev-
eral databases and has precise longitudinal follow-up
data due to unique civil registration numbers. This is a
major strength since the study is performed on all hip
fracture patients and therefore reflects the true clinical
value of a restrictive RBC transfusion strategy.
Conclusion
These data suggest that the introduction of an NCG
on restrictive blood transfusion leads to lower trans-
fusion frequency in hip fracture patients > 65 years
old. Even though this reduction is associated with
decreased mortality at both 30 and 90 days, it may be
explained by other issues than restrictive transfusion
strategy. There has been an improvement in the mor-
tality of hip fracture patients in Denmark, and we
suggest that a restrictive transfusion strategy does not
lead to increased mortality.
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